| CASE REPORT |
|
| Year : 2017 | Volume
: 27
| Issue : 1 | Page : 58-61 |
Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced
SK Sethi1, S Rohatgi1, MA Dragon-Durey2, V Raghunathan3, M Dhaliwal3, A Rawat1, P Jha1, SB Bansal1, R Raina4, V Kher1
1 Department of Nephrology, Kidney and Urology Institute, Medanta, The Medicity, Gurgaon, Haryana, India
2 INSERM UMRS 1138, Team 10 and Paris Descartes University, Paris, France
3 Pediatric Intensive Care, Medanta, The Medicity, Gurgaon, Haryana, India
4 Department of Pediatric Nephrology, Akron Children's Hospital, Cleveland, Ohio, USA
Correspondence Address:
S K Sethi
Consultant, Pediatric Nephrology, Kidney and Urology Institute, Medanta, The Medicity, Gurgaon - 122 001, Haryana
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0971-4065.179369
Much progress has been made in understanding the pathophysiology and treatment of atypical hemolytic uremic syndrome (aHUS). Plasma therapy is the mainstay of treatment for aHUS. The availability of the first effective anti-complement therapeutic agent, eculizumab, has dramatically changed the outlook of this disease. However, its use in clinical practice raises important questions, such as who should receive the drug, when to start such therapy, and is it safe to stop treatment once the disease is controlled. We describe here for the 1st time in India, use of eculizumab in a 12-year-old boy with aHUS. We also describe in this report challenges faced in procuring the drug, and an ideal, evidence-based method of treating aHUS in children.
[FULL TEXT] [PDF]*
|
|
Editorial Board
